EOS-448 is an anti-TIGIT human immunoglobulin G1, or IgG1, antibody that we are developing to inhibit the immunosuppressive activity of TIGIT. TIGIT is a cell surface receptor expressed on multiple immune cells, including CD8+ T cells, natural killer, or NK, cells and T regulatory cells, or Tregs, a cell population that inhibits the immune response.

EOS-984 is a potential first-in-class small molecule in oncology inhibiting ENT1 that we are developing to reverse suppression of the immune system’s response and restore T cell proliferation in the tumor microenvironment. ENT1 is a dominant transporter of extracellular adenosine on T cells in the tumor which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival.

EOS-215 is a potential best-in-class anti-TREM2 (anti-Triggering Receptor Expressed on Myeloid Cells 2) antibody that we are developing to inhibit the multi-faceted immunosuppressive activity of TREM2. In normal conditions, TREM2 regulates myeloid cells, primarily macrophages, to maintain tissue homeostasis by controlling inflammation and promoting tissue repair. When cancer hijacks TREM2 signaling, it allows for metabolic reprogramming, unregulated efferocytosis, immunosuppression from tumor-associated macrophages (TAMs), tumor growth via angiogenesis, and immune system evasion and survival via fibrotic remodeling in the tumor microenvironment.